CMXC:OTCPK (USA)

Cell MedX Corp

$ 0.17 0 (0%)
Volume: 150,000 Avg Vol (1m): 5,546
Market Cap $: 7.53 Mil Enterprise Value $: 7.70 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -0.23
Net Current Asset Value -0.03
Tangible Book -0.03
Projected FCF -0.12
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt 0.12
Debt-to-Equity -0.14
Debt-to-EBITDA -0.20
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -141.48
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC -1.66%

Profitability & Growth : 3/10

Current vs industry vs history
ROA % -617.65
ROC (Joel Greenblatt) % -2271.57
3-Year Total Revenue Growth Rate -100.00
3-Year Total EBITDA Growth Rate -14.50
3-Year EPS w/o NRI Growth Rate -10.10

» CMXC's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with OTCPK:CMXC

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Conglomerates » Conglomerates    NAICS : 551112    SIC : 6719
Compare TSXV:ARIC TSXV:SVS OTCPK:AASP OTCPK:UPDC OTCPK:PVNC OTCPK:USDF OTCPK:ADAC XKLS:9091 TSXV:SIQ BOM:540394 XSGO:REBRISA-B LSE:DERR TSXV:OIC FRA:RKB OTCPK:TFLG BOM:520081 OTCPK:NCRE OTCPK:BOTH OTCPK:NGLD BSP:NORD3
Traded in other countries
Address 123 W. Nye Ln, Suite 446, Carson City, NV, USA, 89706
Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications. The company's product portfolio consists of electromedical technologies, ebalance, and others. The revenue of the company consists of sales of spa equipment and consumable products, as well as continuing education courses to estheticians and healthcare professionals in the field of medical aesthetics.

Ratios

Current vs industry vs history
EV-to-EBIT -8.61
EV-to-EBITDA -7.92
Current Ratio 0.06
Quick Ratio 0.02

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -12.60

Valuation & Return

Current vs industry vs history
Earnings Yield (Joel Greenblatt) % -11.61

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N